Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status
Chemotherapy · 2024 · 69 (3) · 141-149
DOI: 10.1159/000537874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemotherapy, online erschienen am 16.02.2024. Verfasst von Goncagul Akdag und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Ki-67 Antigen, Neoadjuvant Therapy, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Neoadjuvant chemotherapy (NAC) is extensively employed in breast cancer (BC), primarily for aggressive subtypes like triple-negative and human epidermal growth factor receptor 2 (HER2)-positive BC and in estrogen receptor-positive (ER+)/HER2− BC with high-risk features. In ER+/HER2− BC, pathological complete rates are much lower (<10%), while axillary dissection rates are higher. This study focuses on hormone receptor-positive (HR+)/HER2− BC patients undergoing NAC, examining its impact on pathological complete response (pCR) rates, with specific attention to tumor Ki67 and ER status.
Methods
Retrospective data analysis from Kartal Dr. Lütfi Kırdar City Hospital included HR+/HER2− BC patients who received NAC. Clinicopathological factors, NAC response, and surgical outcomes were assessed. Statistical analyses evaluated the association between Ki67, ER status, and pCR.
Results
Of 203 patients, 11.8% achieved pCR. Ki67 (p < 0.001) and ER percentage (p < 0.001) significantly correlated with pCR. Higher Ki67 was associated with increased pCR likelihood (HR: 1.03, 95% CI: 1.01–1.05). A Ki67-pCR probability curve revealed a cutoff of 23.5%. ER%-pCR analysis showed decreasing pCR rates with higher ER percentages. Multivariate analysis confirmed Ki67 (p = 0.003, HR: 1.02) and ER percentage (p = 0.019, HR: 0.97) as independent predictors of pCR probability.
Conclusion
Consideration of Ki67 and ER percentage aids in NAC decisions for HR+/HER2− BC, identifying patients with high NAC response rates, facilitating axillary preservation, and potentially avoiding axillary dissection. The pCR rates in patients with Ki67 ≤24 are particularly low, especially in patients with a high ER percentage. In these cases, upfront surgery and adjuvant treatment should be considered instead of NAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul, Turkey.
- Division of Medical Oncology, School of Medicine, Koç University, Istanbul, Turkey.
- Department of Pathology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul, Turkey.
Zitieren
APA
Akdag, G., Yildirim, S., Dogan, A., Yuksel Yasar, Z., Bal, H., Kinikoglu, O., Oksuz, S., Ozkerim, U., Tunbekici, S., Yildiz, H. S., Turkoglu, E., Alan, O., Coban Kokten, S., Isik, D., Sever, O. N., Odabas, H., Yildirim, M. E., & Turan, N. (2024). Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status. Chemotherapy, 69(3), 141-149. https://doi.org/10.1159/000537874
Vancouver
Akdag G, Yildirim S, Dogan A, Yuksel Yasar Z, Bal H, Kinikoglu O, et al. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status. Chemotherapy. 2024;69(3):141-149. doi:10.1159/000537874
BibTeX
@article{Akdag2024,
author = {Akdag, Goncagul and Yildirim, Sedat and Dogan, Akif and Yuksel Yasar, Zeynep and Bal, Hamit and Kinikoglu, Oguzcan and Oksuz, Sila and Ozkerim, Ugur and Tunbekici, Salih and Yildiz, Hacer Sahika and Turkoglu, Ezgi and Alan, Ozkan and Coban Kokten, Sermin and Isik, Deniz and Sever, Ozlem Nuray and Odabas, Hatice and Yildirim, Mahmut Emre and Turan, Nedim},
title = {Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status},
journal = {Chemotherapy},
year = {2024},
volume = {69},
number = {3},
pages = {141--149},
doi = {10.1159/000537874}
}
EUVIMED